Phaseline

Targets › DPP3

DPP3 (Dipeptidyl peptidase 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.

Cleaves and degrades bioactive peptides, including angiotensin, Leu-enkephalin and Met-enkephalin. Also cleaves Arg-Arg-beta-naphthylamide (in vitro). (UniProt, Q9NY33)

Open in Phaseline: the race on DPP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
4TEEN4 PharmaceuticalsAK1967 (Invobenitug also known as Procizumab)
DPP3 inhibition using humanized monoclonal antibody
DPP3Phase 1Shock, CardiogenicDec 2026

Conditions

Shock, Cardiogenic (1)

Modalities

antibody (1)

Companies

4TEEN4 Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.